Heartflow (NASDAQ:HTFL) Shares Down 7.4% Following Insider Selling

Shares of Heartflow, Inc. (NASDAQ:HTFL) traded down 7.4% on Tuesday following insider selling activity. The company traded as low as $26.73 and last traded at $27.13. 1,594,640 shares traded hands during trading, an increase of 15% from the average session volume of 1,386,446 shares. The stock had previously closed at $29.29.

Specifically, CEO John C.M. Farquhar sold 22,562 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $27.46, for a total transaction of $619,552.52. Following the sale, the chief executive officer owned 591,656 shares in the company, valued at $16,246,873.76. The trade was a 3.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Julie A. Cullivan sold 8,000 shares of the stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $27.32, for a total value of $218,560.00. Following the completion of the sale, the director directly owned 36,413 shares of the company’s stock, valued at approximately $994,803.16. This represents a 18.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In other news, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $28.05, for a total value of $56,100,000.00. Following the completion of the sale, the insider directly owned 10,448,158 shares of the company’s stock, valued at $293,070,831.90. This represents a 16.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Analyst Ratings Changes

A number of research firms have recently weighed in on HTFL. JPMorgan Chase & Co. raised their price target on Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Canaccord Genuity Group upped their price objective on shares of Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Wells Fargo & Company assumed coverage on Heartflow in a report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price target on the stock. Finally, Stifel Nicolaus lifted their target price on shares of Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $38.50.

Heartflow News Roundup

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Brokerages have raised price targets and added coverage (Wells Fargo started coverage with an “overweight”; JPMorgan, Stifel and Canaccord have lifted targets near $38–$40), which supports medium‑term upside expectations.
• Neutral Sentiment: Small institutional buys have shown modest inflows from several funds in recent quarters — a limited vote of confidence but not large enough to counter recent selling.
• Negative Sentiment: CEO John C.M. Farquhar sold 22,562 shares at about $27.46 (~$619.6k), trimming his stake — insider selling by the CEO can sap near‑term sentiment and supply. Insider Selling: CEO Form 4
• Negative Sentiment: Director Julie Cullivan sold 8,000 shares at about $27.32 (~$218.6k), cutting her holding ~18% — additional insider sales amplify negative optics. Director Sale
• Negative Sentiment: Short interest surged in late January to ~4.95M shares (up ~42% vs. mid‑January), representing roughly 5.8% of float and a ~5.9 days‑to‑cover — higher short positioning can amplify downside on negative news and increases selling pressure.
• Negative Sentiment: Reports of a large shareholder sell‑off (headline coverage cited a multi‑million dollar block sale) likely added supply and weighed on the stock. Major Shareholder Sale

Heartflow Price Performance

The stock’s 50-day simple moving average is $30.24. The company has a market cap of $2.30 billion and a PE ratio of -14.89.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Wellington Management Group LLP acquired a new position in Heartflow in the third quarter worth $164,263,000. Baillie Gifford & Co. bought a new stake in shares of Heartflow during the third quarter valued at approximately $101,182,000. Schusterman Interests LLC acquired a new stake in shares of Heartflow in the third quarter valued at approximately $65,274,000. Vanguard Group Inc. lifted its holdings in Heartflow by 8.8% during the 4th quarter. Vanguard Group Inc. now owns 1,580,313 shares of the company’s stock worth $46,066,000 after buying an additional 128,400 shares in the last quarter. Finally, Capital International Investors acquired a new stake in shares of Heartflow in the 3rd quarter valued at $43,671,000.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.